Core Viewpoint - Yangguang Nuohuo (688621) aims to enhance its strategic layout in CAR-T cell therapy and nucleic acid drugs by investing 15 million yuan in Shanghai Yuanma Zhiyao Biotechnology Co., Ltd., acquiring an 8.2% stake after the capital increase [1] Group 1: Investment Details - The company will use its own funds to invest 15 million yuan to subscribe for an additional registered capital of 110,556 yuan in Yuanma Zhiyao [1] - After the capital increase, Yangguang Nuohuo will hold an 8.2% equity stake in Yuanma Zhiyao [1] Group 2: Company Focus - Yuanma Zhiyao specializes in the innovation and research of circular mRNA in vivo CAR-T nucleic acid drugs [1] - The company aims to achieve "cell therapy effects" through "nucleic acid drug forms," addressing commercialization challenges in CAR-T therapy [1] Group 3: Research and Development Progress - Yuanma Zhiyao has completed early-stage research on multiple pipelines, including circular mRNA in vivo CAR-T, and is rapidly advancing towards clinical research [1] - The company is expected to become the first globally to enter clinical trials with modified circular mRNA in vivo CAR-T therapy [1]

Core Viewpoint - Sunshine Nuohuo (688621.SH) announced an investment of 15 million yuan to subscribe for an increase in registered capital of Yuanma Zhiyao by 110,556 yuan, resulting in an 8.20% equity stake in the company, which focuses on innovative research and development of circular mRNA CAR-T nucleic acid drugs [1] Group 1 - The investment aims to advance the overall strategic layout in the field of in vivo CAR-T cell therapy and nucleic acid drugs [1] - Yuanma Zhiyao has completed early-stage research on multiple pipelines, including in vivo CAR-T with circular mRNA, and is rapidly progressing towards clinical research [1] - The company is expected to become the first globally to enter clinical trials for modified circular mRNA in vivo CAR-T therapy [1]